Learning the value of drugs--is rofecoxib a regulatory success story?
Eisenberg
Rebecca S
RS
University of Michigan Law School, Ann Arbor, USA.
D002318:Cardiovascular Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic / Q000191:economics; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D017277:Drug Approval / Q000191:economics*; D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence; D033161:Government Regulation; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D011358:Product Surveillance, Postmarketing; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib